Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05049057
PHASE2

Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI

Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine

View on ClinicalTrials.gov

Summary

This study aims to assess the effect and safety of erenumab compared to placebo for the treatment of acute posttraumatic headache (PTH) in military service members and civilians with mild traumatic brain injury (mTBI).

Official title: Treatment of Acute Post-Traumatic Headache With Erenumab 140 mg, Military Service Members and Civilians With Mild TBI: A Randomized, Double Blind, Placebo Controlled, Multicenter 12-week Duration Study Followed by a 4-week Open-Label Safety Extension

Key Details

Gender

All

Age Range

18 Years - 50 Years

Study Type

INTERVENTIONAL

Enrollment

404

Start Date

2022-07-19

Completion Date

2027-05-19

Last Updated

2024-02-22

Healthy Volunteers

No

Interventions

DRUG

Erenumab 140 Mg/mL Subcutaneous Solution

Active erenumab delivered via subcutaneous injection.

DRUG

Placebo

Placebo delivered via subcutaneous injection.

Locations (4)

Womack Army Medical Center - Fort Liberty

Fort Bragg, North Carolina, United States

University of Pittsburgh Concussion Research Laboratory

Pittsburgh, Pennsylvania, United States

William Beaumont Army Medical Center

El Paso, Texas, United States

Madigan Army Medical Center

Tacoma, Washington, United States